ES3014024T3 - Buffered formulations of exendin (9-39) - Google Patents

Buffered formulations of exendin (9-39) Download PDF

Info

Publication number
ES3014024T3
ES3014024T3 ES17871296T ES17871296T ES3014024T3 ES 3014024 T3 ES3014024 T3 ES 3014024T3 ES 17871296 T ES17871296 T ES 17871296T ES 17871296 T ES17871296 T ES 17871296T ES 3014024 T3 ES3014024 T3 ES 3014024T3
Authority
ES
Spain
Prior art keywords
exendin
formulation
dose
liquid pharmaceutical
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17871296T
Other languages
English (en)
Spanish (es)
Inventor
Xiaofeng Xiong
Debra Odink
Colleen M Craig
Christine M N Smith
Tracey L Mclaughlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Amylyx Pharmaceuticals Inc
Original Assignee
Leland Stanford Junior University
Amylyx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University, Amylyx Pharmaceuticals Inc filed Critical Leland Stanford Junior University
Application granted granted Critical
Publication of ES3014024T3 publication Critical patent/ES3014024T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES17871296T 2016-11-21 2017-11-21 Buffered formulations of exendin (9-39) Active ES3014024T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662424979P 2016-11-21 2016-11-21
US201762517065P 2017-06-08 2017-06-08
PCT/US2017/062838 WO2018094404A1 (en) 2016-11-21 2017-11-21 Buffered formulations of exendin (9-39)

Publications (1)

Publication Number Publication Date
ES3014024T3 true ES3014024T3 (en) 2025-04-16

Family

ID=62145888

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17871296T Active ES3014024T3 (en) 2016-11-21 2017-11-21 Buffered formulations of exendin (9-39)

Country Status (20)

Country Link
US (4) US11020484B2 (https=)
EP (2) EP4591853A1 (https=)
JP (4) JP7584894B2 (https=)
CN (1) CN110267648A (https=)
AU (3) AU2017361539B2 (https=)
CA (1) CA3043899A1 (https=)
CL (1) CL2019001366A1 (https=)
DK (1) DK3541366T3 (https=)
ES (1) ES3014024T3 (https=)
FI (1) FI3541366T3 (https=)
HR (1) HRP20250278T1 (https=)
HU (1) HUE070730T2 (https=)
IL (1) IL266568B2 (https=)
LT (1) LT3541366T (https=)
PL (1) PL3541366T3 (https=)
PT (1) PT3541366T (https=)
RS (1) RS66595B1 (https=)
SI (1) SI3541366T1 (https=)
SM (1) SMT202500120T1 (https=)
WO (1) WO2018094404A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3456340T1 (sl) 2007-01-08 2022-08-31 The Trustees Of The University Of Pennsylvania Antagonisti receptorja za GLP-1 za uporabo pri zdravljenju prirojenega hiperinsulinizma
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
AU2016267052B2 (en) 2015-05-22 2022-01-20 The Bot Of The Leland Stanford Junior University Treatment of post-bariatric hypoglycemia with GLP-1 antagonists
US10653753B2 (en) 2016-03-04 2020-05-19 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
EP4591853A1 (en) 2016-11-21 2025-07-30 Amylyx Pharmaceuticals, Inc. Buffered formulations of exendin (9-39)
BR112019026711A2 (pt) 2017-06-16 2020-06-30 Zealand Pharma A/S regimes de dosagem para a administração de análogos de peptídeo semelhante a glucagon- 2 (glp-2)
EP3628683A1 (en) * 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
IL314504A (en) * 2018-10-15 2024-09-01 Eiger Biopharmaceuticals Inc Abexitide for the treatment of hyperinsulinemic hypoglycemia
AU2021270284A1 (en) 2020-05-12 2023-01-05 Regeneron Pharmaceuticals, Inc. Anti-GLP1R antagonist antibodies and methods of use thereof
WO2022271753A1 (en) 2021-06-21 2022-12-29 Eiger Biopharmaceuticals, Inc. Treatment of congenital hyperinsulinism with avexitide
US11878036B2 (en) * 2022-05-25 2024-01-23 Neuvian LLC Vaginal care compositions and methods of improving vaginal health
CN116606367A (zh) * 2022-05-31 2023-08-18 南京盛德瑞尔医药科技有限公司 长效Exendin-9-39及其在低血糖治疗中的应用和作为治疗低血糖的药物
AU2024258693A1 (en) * 2023-04-21 2025-10-09 Amylyx Pharmaceuticals, Inc. Glp-1r antagonism to improve nutrition following gastrointestinal surgery

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK155694A3 (en) 1992-06-15 1995-05-10 Pfizer Glucagon-like peptide, insulinotropin derivatives, method of their preparation, pharmaceutical agent containing and using these matters
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US20040092443A1 (en) 1996-08-06 2004-05-13 Yeda Research And Development Co., Ltd Long-acting exendins and exendin agonists
WO1998005351A1 (en) 1996-08-08 1998-02-12 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
EP0996459B1 (en) 1997-01-07 2005-09-21 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
DE69900026T2 (de) 1998-01-30 2001-05-10 Novo Nordisk As Eine injektionsspritze
ATE288268T1 (de) 1998-12-10 2005-02-15 Agouron Pharma Nichtpeptidische antagonisten des glp-1 rezeptors und verwendungsmethoden
DK1143989T3 (da) 1999-01-14 2007-04-16 Amylin Pharmaceuticals Inc Exendiner til glucagonundertrykkelse
NZ512663A (en) * 1999-01-14 2004-05-28 Amylin Pharmaceuticals Inc Novel exendin agonist formulations and methods of administration thereof
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6903074B1 (en) 1999-06-04 2005-06-07 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Neuromedin b and somatostatin receptor agonists
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6479065B2 (en) 2000-08-10 2002-11-12 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
SE0004462D0 (sv) 2000-12-04 2000-12-04 Pharmacia Ab Novel method and use
WO2002066062A2 (en) 2001-02-01 2002-08-29 Drucker Daniel J Enhancement of glp-2 activity
WO2002081649A2 (en) 2001-04-06 2002-10-17 The Trustees Of The University Of Pennsylvania ErbB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
CA2452044A1 (en) * 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
US7378385B2 (en) 2002-08-08 2008-05-27 University Of Cincinnati Role for GLP-1 to mediate responses to disparate stressors
TR201906789T4 (tr) 2003-11-20 2019-05-21 Novo Nordisk As Üretim ve enjeksiyon cihazlarında kullanım için en uygun olan propilen glikol ihtiva eden peptit formülasyonları.
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
SI2409707T1 (sl) 2004-04-15 2015-07-31 Alkermes Pharma Ireland Limited Naprava s podaljšanim sproščanjem na osnovi polimerov
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
DE102004043153B4 (de) 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
CA2609810C (en) 2005-06-06 2012-05-22 Camurus Ab Glp-1 analogue formulations
ES2736184T3 (es) 2005-08-19 2019-12-26 Amylin Pharmaceuticals Llc Exendina para el tratamiento de la diabetes y la reducción del peso corporal
MX2008013508A (es) * 2006-04-21 2008-10-31 Novartis Ag Composiciones farmaceuticas de anticuerpos antagonistas anti-cd40.
AU2007267833B2 (en) * 2006-05-26 2012-07-26 Amylin Pharmaceuticals, Llc Composition and methods for treatment of congestive heart failure
SI3456340T1 (sl) 2007-01-08 2022-08-31 The Trustees Of The University Of Pennsylvania Antagonisti receptorja za GLP-1 za uporabo pri zdravljenju prirojenega hiperinsulinizma
EP2144649B1 (de) 2007-04-05 2011-07-20 Tecpharma Licensing AG Verabreichungsvorrichtung mit funktionalem antriebsglied
DE102007016811A1 (de) 2007-04-05 2008-10-09 Tecpharma Licensing Ag Vorrichtung zur Verabreichung eines fluiden Wirkstoffes aus einer Mehrkammerampulle
HRP20130259T1 (hr) 2007-04-23 2013-04-30 Intarcia Therapeutics, Inc. Suspenzijske formulacije inzulinotropnih peptida i njihove uporabe
CN105903005A (zh) 2008-05-05 2016-08-31 奥拉姆德有限公司 用于口服给予艾塞那肽的方法和组合物
EP2303313B1 (en) 2008-05-21 2015-10-28 Amylin Pharmaceuticals, LLC Exendins to lower cholestrol and triglycerides
WO2009158412A2 (en) 2008-06-25 2009-12-30 Endo Pharmaceuticals Solutions Inc. Sustained delivery of exenatide and other polypeptides
PL2310042T3 (pl) 2008-07-08 2013-05-31 Novartis Ag Zastosowanie pasyreotydu do leczenia endogennej hipoglikemii hiperinsulinemicznej
KR101760953B1 (ko) 2008-09-04 2017-07-24 아밀린 파마슈티칼스, 엘엘씨. 비-수성 담체를 이용한 서방성 제형물
BRPI1014065A2 (pt) 2009-04-03 2016-04-12 Nestec Sa melhora na promoção do crescimento compensatório saudável
JP5839597B2 (ja) 2009-06-08 2016-01-06 アムニクス オペレーティング インコーポレイテッド グルコース調節ポリペプチド並びにその作成及び使用方法
WO2011109787A1 (en) * 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
WO2012012352A2 (en) 2010-07-19 2012-01-26 Amidebio, Llc Modified peptides and proteins
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US20140256626A1 (en) 2011-10-18 2014-09-11 Prolynx Llc Peg conjugates of exenatide
WO2013120022A2 (en) 2012-02-08 2013-08-15 Seneb Biosciences, Inc. Treatment of hypoglycemia
JP6265970B2 (ja) * 2012-03-26 2018-01-24 サノフイ 安定なＩｇＧ４に基づく結合剤の製剤
HK1226084A1 (zh) 2013-08-16 2017-09-22 Medimmune Limited 用於治疗糖尿病的gip和glp-1受体双重激动剂
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AU2016267052B2 (en) * 2015-05-22 2022-01-20 The Bot Of The Leland Stanford Junior University Treatment of post-bariatric hypoglycemia with GLP-1 antagonists
US10653753B2 (en) 2016-03-04 2020-05-19 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
EP4591853A1 (en) * 2016-11-21 2025-07-30 Amylyx Pharmaceuticals, Inc. Buffered formulations of exendin (9-39)

Also Published As

Publication number Publication date
JP2022153624A (ja) 2022-10-12
IL266568B1 (en) 2024-05-01
JP2026048629A (ja) 2026-03-17
US20200069802A1 (en) 2020-03-05
IL266568A (en) 2019-07-31
IL266568B2 (en) 2024-09-01
EP3541366B1 (en) 2024-12-25
AU2025205195A1 (en) 2025-07-24
PL3541366T3 (pl) 2025-04-28
FI3541366T3 (fi) 2025-03-06
HUE070730T2 (hu) 2025-06-28
CA3043899A1 (en) 2018-05-24
EP3541366A1 (en) 2019-09-25
US20240042035A1 (en) 2024-02-08
AU2017361539B2 (en) 2023-06-29
JP7584894B2 (ja) 2024-11-18
LT3541366T (lt) 2025-03-10
DK3541366T3 (da) 2025-03-03
AU2017361539A1 (en) 2019-07-04
US20210315995A1 (en) 2021-10-14
EP3541366A4 (en) 2020-08-05
WO2018094404A1 (en) 2018-05-24
SMT202500120T1 (it) 2025-05-12
JP2019535734A (ja) 2019-12-12
US11020484B2 (en) 2021-06-01
PT3541366T (pt) 2025-03-14
CL2019001366A1 (es) 2019-11-08
HRP20250278T1 (hr) 2025-04-25
JP2024150450A (ja) 2024-10-23
AU2023237119A1 (en) 2023-10-19
CN110267648A (zh) 2019-09-20
SI3541366T1 (sl) 2025-05-30
RS66595B1 (sr) 2025-04-30
BR112019010236A2 (pt) 2019-08-20
US11738086B2 (en) 2023-08-29
AU2023237119B2 (en) 2025-04-10
EP4591853A1 (en) 2025-07-30
US20260034221A1 (en) 2026-02-05

Similar Documents

Publication Publication Date Title
ES3014024T3 (en) Buffered formulations of exendin (9-39)
US12220444B2 (en) Treatment of hyperinsulinemic hypoglycemia with GLP-1 antagonist exendin(9-39)
JP2019535734A5 (https=)
ES2442869T3 (es) Usos de formulaciones duraderas de péptidos GLP-1 como hipoglucémicos
KR20230026984A (ko) 비양성자성의 극성 용매 중의 안정한 지속 방출성 치료 조성물 및 그의 제조 방법
US20240350590A1 (en) Composition for orally administered formulation containing glp-1 analogue
BR112021006968A2 (pt) avexitide para o tratamento da hipoglicemia hiperinsulinêmica
HK40014636B (en) Buffered formulations of exendin (9-39)
HK40014636A (en) Buffered formulations of exendin (9-39)
BR112019010236B1 (pt) Formulações tamponadas de exendina (9-39) e uso das mesmas
BR122025006444A2 (pt) Formulações tamponadas de exendina (9-39)